BriaCell Therapeutics Corp.

BCT

CA1079303071

Biotechnology & Medical Research

Market Closed - Toronto S.E. 03:50:20 2026-10-01 pm EDT			5-day change	1st Jan Change
5.880 ^CAD	-3.61%		-2.33%	-40.00%

Sep. 14	BriaCell Therapeutics Corp Receives Seventh Consecutive Positive DSMB Recommendation For Pivotal Phase 3 Bria-ABC Study Of Bria-IMT Plus Immune Checkpoint Inhibitor	CI
Sep. 11	Neonc Technologies Holdings, Briacell Therapeutics and Oncolytics Biotech Have Report Clinical and Regulatory Developments Across Brain, Breast and Colorectal Cancer	CI

Top Premarket Decliners

Published on 01/14/2026 at 07:57 am EST

MT Newswires

This article is reserved for our members.

Continue with Google Continue with Apple Continue with LinkedIn

or by email

Continue with an email.

Latest news about BriaCell Therapeutics Corp.

Sep. 14	BriaCell Therapeutics Corp Receives Seventh Consecutive Positive DSMB Recommendation For Pivotal Phase 3 Bria-ABC Study Of Bria-IMT Plus Immune Checkpoint Inhibitor	CI
Sep. 11	Neonc Technologies Holdings, Briacell Therapeutics and Oncolytics Biotech Have Report Clinical and Regulatory Developments Across Brain, Breast and Colorectal Cancer	CI
Sep. 08	BriaCell Therapeutics Corp. Expands Pivotal Phase 3 Metastatic Breast Cancer Study To Memorial Sloan Kettering Cancer Center	CI
Sep. 01	Certain Common Shares of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026.	CI
Sep. 01	Certain Warrants of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026.	CI
Sep. 01	Certain Options of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026.	CI
Sep. 01	Certain Restricted Share Units of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026.	CI
Sep. 01	Certain Performance Share Units of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026.	CI
Aug. 24	BriaCell Therapeutics Corp. Advances Personalized Melanoma Immunotherapy Vaccine Candidate Bria-MEL+	CI
Aug. 05	BriaCell Gets FDA Approval to Start Phase 1/2a of Prostate Cancer Immunotherapy Study	MT
Aug. 05	Briacell Therapeutics Corp Receives Fda Clearance to Initiate Bria-Pros+ Clinical Study in Prostate Cancer	CI
Jul. 16	BriaCell Opens First Canadian Site For Phase 3 Metastatic Breast Cancer Study	MT
Jul. 16	BriaCell Therapeutics Corp. Opens First Canadian Site For Pivotal Phase 3 Trial In Metastatic Breast Cancer	CI
Jul. 07	BriaCell Engages Consulting and Branding Firms to Support Potential Commercialization of Bria-IMT	MT
Jun. 25	BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT	CI

Chart BriaCell Therapeutics Corp.

Duration

Period

BCT: Dynamic Chart

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patientâ€™s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.

Employees

Sector

Biotechnology & Medical Research

More about the company